This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mercer, G. Articles by Owens, D. G. C. Search for Related Content PubMed PubMed Citation Articles by Mercer, G. Articles by Owens, D. G. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CHLORAZINE CHLORPROMAZINE Medline Plus Health Information Schizophrenia Social Bookmarking                         What's this?

A study of enhanced management in patients with treatment-resistant schizophrenia

University Department of Psychiatry, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF, UK

Alan Finlayson

University Department of Psychiatry, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF, UK

Eve C. Johnstone

University Department of Psychiatry, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF, UK

Claire Murray

University Department of Psychiatry, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF, UK

David G. C. Owens

University Department of Psychiatry, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF, UK

The clinical efficacy of two intensive treatment packages (one including the new antipsychotic risperidone and the other not doing so) was compared with that of standard management in 43 patients with long-standing treatment-resistant schizophrenia. Significant differences between the groups in terms of total positive or total negative symptoms were not demonstrated, but the pattern of change between the treatment groups differed, so that benefit in positive symptomatology was seen in both intensive treatment groups and in negative symptomatology in the intensive treatment/risperidone group and the standard group. Changes in general psychopathology were most marked in the risperidone group and were compatible with a relatively non-sedative profile. Using the Disability Assessment Schedule, substantial significant advantages for the intensive treatment groups were found.

Key Words: intensive management • risperidone • social function • symptomatic change • treatment-resistant schizophrenia

Journal of Psychopharmacology, Vol. 11, No. 4, 349-356 (1997)
DOI: 10.1177/026988119701100411


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?